Comparison of Myoinositol and Metformin in PCO
Comparison of Myoinositol and Metformin in PCO
Aim of the study is to compare the effect of myoinositol and metformin in the resumption of
 the spontaneous menstrual cycle in patients diagnosed with PCOS or having oligo/amenorrhea,
 reduction in weight and BMI, Improvement in the biochemical and clinical profile of patients
 with the polycystic syndrome.

 The secondary outcome measured will be the rate of pregnancy, miscarriage and term pregnancy
 among these patients inducted in the study.

 It will be a Three-arm prospective double-blind study. this clinical trial will be registered
 in Public registry. this RCT will be based on CONSORT statement. The patient coming to
 Gynecology OPD will be randomized into 3 groups GROUP A ( metformin 500 mg TDS), GROUP B(
 myoinositol 2mg x BD ), GROUP C.(both metformin,& myoinositol).each group will take folic
 acid and will be asked for lifestyle modifications.
PCOS is a common endocrine disorder in women of reproductive age associated with insulin
 resistance. Metformin and Myo-inositol being insulin sensitizers improve biochemical
 parameters. it is aimed to compare the effect of myoinositol and metformin in the resumption
 of the spontaneous menstrual cycle in patients diagnosed with PCOS or having
 oligo/amenorrhea, reduction in weight and BMI, Improvement in the biochemical and clinical
 profile of patients with the polycystic syndrome.

 Inclusion criteria: will be based on the Rotterdam criteria of diagnosing PCO. Patients
 presenting with a history of secondary amenorrhea, irregular menstrual cycle, oligomenorrhea,
 weight gain, hirsutism, and already diagnosed cases of PCO will be included in this group.

 Patients with history of Hyperprolactinemia, Cushing's disease, Hypothyroidism/
 Hyperthyroidism, Pregnancy and nursing, Established type 1 or type 2 diabetes mellitus, Any
 history of drug intake e.g. anti-diabetic or estrogen and progesterone, History of treatment
 for the same complaint taken in the last 3 months, Unable to come for regular follow-ups, Any
 pathological cause of bleeding e.g. Fibroid, Polyp, Cervical pathology and known allergic to
 these drugs would be excluded.
Inclusion Criteria:

 It will be based on the Rotterdam criteria of diagnosing PCO. Patients presenting with a
 history of secondary amenorrhea, irregular menstrual cycle, oligomenorrhea, weight gain,
 hirsutism, and already diagnosed cases of PCO will be included in this group.

 Exclusion Criteria:

 -  Hyperprolactinemia

 -  Cushing's disease

 -  Hypothyroidism/ Hyperthyroidism

 -  Pregnancy and nursing

 -  Established type 1 or type 2 diabetes mellitus

 -  Any history of drug intake e.g. anti-diabetic or estrogen and progesterone

 -  History of treatment for the same complaint taken in the last 3 months

 -  Unable to come for regular follow-ups

 -  Any pathological cause of bleeding e.g. Fibroid, Polyp, Cervical pathology

 -  Known allergic to these drugs